• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Walk test linked to quality of life in multiple sclerosis

byAshley AaroeandJames Jiang
September 2, 2014
in Chronic Disease, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The timed 25-foot walk (T25-FW) test is a means for assessing disability due to walking impairment in multiple sclerosis.

2. Decreases in T25-FW walking speed of 20-25% were associated with significant decreases in patient-reported quality of life scales.

Evidence Rating Level: 2 (Good)

Study Rundown: Multiple sclerosis (MS) is a chronic demyelinating disease which results in a variety of disability-causing symptoms, including sensory loss, spasticity, weakness, and incoordination of the limbs. Past studies demonstrated that many patients with MS report their ability or inability to walk as being the most important factor in terms of quality of life. This study sought to validate the timed 25-foot walk (T25-FW) test, a part of the more comprehensive Multiple Sclerosis Functional Composite (MSFC), relative to patient-reported quality of life scales. The authors emphasized a need to correlate physician-generated outcome measures with patient-generated outcome measures.

This study found that decreases in T25-FW walking speed of 20-25% were associated with significant declines (greater than 5 point decrease) in the SF-36. A strength of this study is that patients were included from various treatment centers. Those with relapsing-remitting and secondary-progressive MS were both included, as were patients on placebo therapy or active therapy with natalizumab and other agents. In this diverse population, walking speed was found to be a clinically meaningful data point for quantifying the progression of MS. This study is limited by the post hoc analysis design, which inherently is at risk to commit a type 1 error. Moreover, the study examines clinical trials, which have specific exclusion criteria, so the results may not be generalizable to all patients.

Click to read the study, published today in JAMA Neurology

Relevant Reading: The impact of slower walking speed on activities of daily living in patients with multiple sclerosis

RELATED REPORTS

United States medical cannabis registration increased significantly between 2016 and 2020

Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis

Differences in national strategies for the treatment of relapsing-remitting multiple sclerosis significantly associated with disability outcomes during follow-up

In-Depth [post hoc analysis]: This study retrospectively analyzed data from three clinical trials, including a total of 2549 patients (AFFIRM, IMPACT, and SENTINEL). The T25-FW test consisted of a having a patient walk (with an aid if necessary) as fast as they could over a 25 foot long course. After two trials, the average time was used to calculate the speed (25 feet/time in seconds to complete course). Patients also completed the SF-36, a 36 item questionnaire that can be scored from 0-100, with higher scores indicating better health-related quality of life.

For all 3 trials, baseline walking speed was positively associated with baseline SF-36 scores (r=0.48, P<0.001). In the subscale analysis, the strongest association was found between the SF-36 subscore for physical functioning and T25-FW scores. Data from the placebo groups of the AFFIRM and IMPACT trials were used for an analysis of mean change from baseline in both T25-FW and SF-36 scores after 2 years. For these patients, the percentage change in walking speed at 2 years was significantly correlated with changes in quality of life on the SF-36 (r=0.35; p<0.001).

More from this author: Deep brain stimulation may be safe for older Parkinson patients,Exome sequencing potentially valuable in diagnosing familial cerebellar ataxias, Functional connectivity similar between autosomal dominant and late onset Alzheimer Disease, Diets rich in omega fatty acids may reduce ALS (Lou Gehrig’s) risk, Increased multiple sclerosis relapse after natalizumab (Tysabri) discontinuation (TY-STOP Study)

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: multiple sclerosis
Previous Post

Overall US diet quality improved from 1999 to 2010

Next Post

Intensity of medical residency may affect future practice style

RelatedReports

Parental cannabis use increasing, cigarette use decreasing
Chronic Disease

United States medical cannabis registration increased significantly between 2016 and 2020

June 29, 2022
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis

October 12, 2021
Quick Take: Safety and Efficacy of Ozanimod Versus Interferon Beta-1a in Relapsing Multiple Sclerosis (SUNBEAM)
Chronic Disease

Differences in national strategies for the treatment of relapsing-remitting multiple sclerosis significantly associated with disability outcomes during follow-up

August 17, 2021
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Improvements in therapeutic and managing standards associated with significant reduction in risk of persistent disability in patients with pediatric-onset multiple sclerosis

June 2, 2021
Next Post
Intensity of medical residency may affect future practice style

Intensity of medical residency may affect future practice style

Low-carb, not low-fat, diet linked with increased weight loss

Low-carb, not low-fat, diet linked with increased weight loss

ADHD stimulant treatment associated with changes in BMI trajectory

Intermittent vagal nerve block ineffective for weight loss in obesity

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.